Ultivue expands its portfolio of Digital Quantitative Pathology Services with a Suite of Image Analysis Capabilities powered by Indica Labs HALO™, HALO LINK™, and Amazon Web Services
CAMBRIDGE, Mass -- September 13, 2018 – Ultivue has announced today the expansion of its menu of Digital Quantitative Pathology Services with a complete suite of Image Analysis capabilities. Building up on the success of its Services group headed up by Dr. Sean Downing, Director of Customer Engagement, Ultivue launches highly customizable image analysis services to complement its core capabilities for fast, mid-to high-level multiplexing custom assay development and high throughput sample staining. “Our InSituPlex™ technology unlocks access to unique, content-rich, whole-slide, tissue-based protein marker information combining quantitative data and spatial resolution. The Ultivue Services Lab leverages the full potential of InSituPlex by providing a wide range of image analysis outputs including phenotypic analysis, cell density determinations, tissue segmentation, and spatial analysis with proximity and nearest neighbor analysis utilizing Indica Labs’ HALO software,” says Dr. Downing.
In collaboration with Amazon Web Services (AWS), Ultivue has built a unique cloud-based ecosystem integrating multiple programs. These include a Laboratory Information Management System (LIMS) platform, image analysis and management systems, and data archiving, thus offering an end-to-end, collaborative platform. This unique ecosystem allows Ultivue’s customers and collaborators to document and submit tissue samples, monitor progress of custom studies, and access to raw and analyzed data.
Ultivue has also selected and implemented Indica Labs’ HALO LINK as its image managing tool to facilitate remote access to data and secure file sharing with its customers across the world. Indica CEO Steven Hashagen added, “HALO LINK is a natural fit for Ultivue’s cloud-based multiplexing services. The platform allows browser-based access to real-time, high-plex analytical data. Recent HALO developments also enable simultaneous analysis of unlimited number of markers, and unlimited number of configurable cell phenotypes; all of which can be scaled within AWS to handle heavy traffic and high throughput demands. We’re pleased our software is an integral part of this exciting offering.”
“Ultivue is a great example of how AWS invests our people, technology and expertise to work alongside customers that are pushing the boundaries of life science R&D,” said Elliot Menschik, MD PhD, Sr. Manager, HCLS VC, AWS Business Development, Amazon Web Services, Inc. who leads the AWS life science practice for investor-backed, private companies. “Building on our best practices and reference architecture for early-stage biotechs, Ultivue challenged us on how best to design a performant and saleable solution that took full advantage of the cloud even in the face of the extraordinary volumes of imaging data they capture from their physical lab operations. It’s rewarding to see that collaboration come to fruition with this launch.”
Ultivue will present the latest developments of its Reagents and Services portfolios on September 13th at 14:55, in the Strategies and Technologies to Deliver Precision Medicine session during the 5th Precision Medicine & Biomarkers Leaders Summit conference, taking place in Munich, Germany.
Ultivue is a venture-backed company developing reagent-driven solutions for high-performance biological imaging in situ, combining unlimited multiplexing at high speed with high spatial resolution. Ultivue’s proprietary solutions enable translational and clinical research groups to realize the promise of personalized medicine through the deciphering of complex mechanisms of cancer onset and progression and the identification of biomarker signatures in tissue samples to better match patients to therapeutic options. The company is committed to commercializing products and services that seamlessly integrate into existing workflows for biomarker discovery, assay validation, and companion diagnostic applications. Ultivue is based in Cambridge, MA.
By developing a single set of novel, proprietary reagents used both for biomarker discovery (higher content, low throughput) and translational use (lower content, high throughput), Ultivue is connecting the insights gained from research directly into the pathology lab. Ultivue’s UltiMapper™ multiplexed assays applied to tissue biopsy samples enable simultaneous quantitation of multiple biomarkers with sub-cellular spatial resolution and fit completely within traditional IHC workflows. Translational and clinical researchers leverage UltiMapper assays to elucidate complex biology and demonstrate their clinical utility as precision medicine research tools. Ultivue is expanding its UltiMapper assay product portfolio and menu of contract research services to provide a comprehensive set of precision medicine solutions for oncology research and focus in other therapeutic areas.
Ultivue is based in Cambridge, MA. For more information, visit www.ultivue.com
For Research Use Only. Not for use in diagnostic procedures.